Oncode Accelerator

Ready for #Runners4Research at #AACR on behalf of Oncode Accelerator!

𝗪𝗵𝗮𝘁'𝘀 𝗻𝗲𝘄 𝗶𝗻 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵? With #ScienceFridays, we not only highlight exciting news from Oncode Accelerator, but also keep a close eye on interesting cancer research news from around the world. In this week's carousel, read about... 💡 Machine Learning-Driven Prognostic Risk Analysis in Metastatic Colorectal Cancer 👉 https://lnkd.in/ea-TAPa6 💡Setting Higher Standards for Reports of Microbial Species in Human Cancers 👉 https://lnkd.in/eAr6Ufjy 💡 Increasing Interest in Degrader-Antibody Conjugates From Big Pharma: Roche & C4 Therapeutics Collaborate 👉https://lnkd.in/eeVeunEV 👉 Follow Oncode Accelerator for more content like this. #cancerresearch #machinelearning #antibodydegraderconjugates 

💪 Mini organs with mega impact… Cumulus Oncology has partnered up with the Organoids Platform of Oncode Accelerator within a new Demonstrator Project. For this, the company will be closely working together with UMC Utrecht’s Onno Kranenburg and his team to develop a new colorectal cancer therapy. Organoids are mini organs or mini tumors grown in labs from real patient material. They can be used to develop medicines, and to test how and if a specific patient will respond to a certain treatment.  Onno Kranenburg (professor of surgical and translational tumor biology) has founded and chairs the UPORT- Utrecht Platform for Organoid Technology. This is a central facility in UMC Utrecht  that stimulates organoid-based biomedical and clinical research.  Onno's Translational Oncology research group is focused on developing new, personalised cancer medicines by integrating fundamental and clinical research. This ensures that patients will have access to the most innovative fundamental research much sooner. “The models that Onno has worked on fit so perfectly with the scientific questions we are trying to answer,” says Clare Doris, Cumulus’ chief development officer.  “We’re absolutely delighted to be working with him.” 📖 More about the new partnership: https://lnkd.in/eXu7tsHx 📖 Info about Onno's Translational Oncology research group: https://lnkd.in/egHr9Ps6 📖 🎥 Get to know the Utrecht Platform for Organoid Technology (UPORT): https://lnkd.in/eAcg9Fq3 #Organoids #TranslationalOncology #ColorectalCancer #CancerResearch

Oncode Accelerator has launched a new Demonstrator Project bringing together UMC Utrecht and JJP Biologics to develop a next-generation bispecific antibody therapy. By combining AI, patient cohorts, and organoid models, the team aims to improve targeting of GD2 — a key protein across multiple cancers — while reducing the severe side effects seen in current treatments. The goal: more effective, safer therapies for neuroblastoma and potentially other cancers. This collaboration highlights how integrated innovation ecosystems are accelerating the path from research to real-world impact in oncology. Read the full article on BiotechNews, the online news and media platform and magazine with a focus on the Dutch and Belgium Life Sciences & Health sector. Get a subscription via the website or follow BiotechNews on LinkedIn to stay up to date on the developments in the Life Sciences sector. https://lnkd.in/emYkBZvY

Together with Oncode Institute and fellow Nationaal Groeifonds Initiatives Biotech Booster, Health-RI and RegMed XB, we're pleased to join today's meeting of the HEALTH CITIES international delegation in Utrecht! HEALTH CITIES is an alliance of European small and medium-sized cities, including representation from ROM Utrecht Region. The initiative aims to improve regional policy instruments that support the development of local, innovative and collaborative ecosystems in the Life Sciences & Health (LSH) industry. The project enhances the capacity of cities to promote entrepreneurship, strengthen value chains, and improve quality of life, by leveraging the economic and social potential of the LSH sector. 💡 Read more: 👉 https://lnkd.in/e9Y7S3c8 👉 https://lnkd.in/dMCrgRQ4 #LSH #innovation #Utrecht Antonietta Impagliazzo, Federica Frati

𝗝𝗼𝗯 𝗩𝗮𝗰𝗮𝗻𝗰𝘆: 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗿 Would you like to join our team as a Business Development Manager? In this role, you'll help turn high-potential scientific opportunities into executable, fundable Demonstrator Projects, operating at the interface of science, partnerships, and funding. Your responsibilities will include: ✅ Opportunity scouting and pipeline development ✅ Early project evaluations and strategic fit reviews, ✅ Stakeholder management ✅ Alliance and partner development ✅ Reporting and team collaboration Read more about the vacancy and apply on our website: https://lnkd.in/egJiyHV5 #career #vacancy #businessdevelopment

As a partner of Oncode Accelerator, TNO brings world-class translational technology and AI-driven insights to the oncology ecosystem. Learn directly from the experts at TNO about how Accelerator Mass Spectrometry and AI-enabled drug target safety assessments can be used to fast-track #oncology innovations👇

𝗪𝗵𝗮𝘁'𝘀 𝗻𝗲𝘄 𝗶𝗻 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵? With #ScienceFridays, we not only highlight exciting news from Oncode Accelerator, but also keep a close eye on interesting cancer research news from around the world. In this week's carousel, read about... 💡From Organoids to Patients: Lessons from the Translational Journey Behind the RASTRIC Trial 👉 https://lnkd.in/eGcEkdG3 💡 Identification of BAP1 Mechanism Points to New Strategy For BAP1-Deficient Pancancer Therapy 👉 https://lnkd.in/ezndxVNb 💡 Injectable Hydrogels for Bio-Macromolecule Delivery to the Tumor Immune Microenvironment 👉 https://lnkd.in/e4RaFUht 👉 Follow Oncode Accelerator for more content like this. Nationaal Groeifonds, Jeanine Roodhart, UMC Utrecht, Cancer Research UMC Utrecht, Hugo Snippert, Maarten Huismans, Oncode Institute #cancerresearch #organoids #translationalresearch

Oncode Accelerator 𝗦𝘂𝗽𝗽𝗼𝗿𝘁𝘀 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗗𝗲𝘃𝗲𝗹𝗼𝗽 𝗡𝗼𝘃𝗲𝗹 𝗡𝗲𝘂𝗿𝗼𝗯𝗹𝗮𝘀𝘁𝗼𝗺𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 A new Demonstrator Project has launched! 🚀 With this project, we are proud to support innovative research from the Antibody therapy group @UMC Utrecht and JJP Biologics, a Polish biotechnology company. 💡 The team will use Oncode Accelerator’s innovation Platforms to develop a novel bispecific antibody therapy against neuroblastoma.  Jeanette Leusen, Professor of Antibody Therapy at UMC Utrecht and lead of the Oncode Accelerator Biologics Workstream says:  "𝘞𝘦 𝘢𝘳𝘦 𝘵𝘩𝘳𝘪𝘭𝘭𝘦𝘥 𝘵𝘰 𝘴𝘵𝘢𝘳𝘵 𝘵𝘩𝘪𝘴 𝘱𝘳𝘰𝘫𝘦𝘤𝘵 𝘰𝘯 𝘯𝘦𝘸𝘭𝘺 𝘦𝘯𝘨𝘪𝘯𝘦𝘦𝘳𝘦𝘥 𝘢𝘯𝘵𝘪𝘣𝘰𝘥𝘪𝘦𝘴 𝘵𝘰 𝘩𝘢𝘳𝘯𝘦𝘴𝘴 𝘰𝘶𝘳 𝘰𝘸𝘯 𝘪𝘮𝘮𝘶𝘯𝘦 𝘴𝘺𝘴𝘵𝘦𝘮 𝘢𝘨𝘢𝘪𝘯𝘴𝘵 𝘴𝘶𝘤𝘩 𝘢 𝘥𝘦𝘢𝘥𝘭𝘺 𝘥𝘪𝘴𝘦𝘢𝘴𝘦 𝘢𝘴 𝘯𝘦𝘶𝘳𝘰𝘣𝘭𝘢𝘴𝘵𝘰𝘮𝘢." Read more: https://lnkd.in/e7QhUmgD Cancer Research UMC Utrecht Louis Boon Nationaal Groeifonds #neuroblastoma #antibodytherapy #bispecificantibody

Great to have TNO on board as a partner of the Oncode Accelerator program. Not only to connect to their Accelerator Mass Spectrometry and Target Safety Assessment capabilities, and integrate these cutting-edge technologies in our integrated value proposition. But also to build on and further expand these technologies within Oncode Accelerator for developing small molecule drugs or biologics. Interested in using these technologies to accelerate your pre-clinical oncology discovery or development project? Check out how to on our website: https://lnkd.in/eyjEYEt7.